Recombinant Anti-CEA x Anti-GD2 Bispecific Antibody (VHH-IgG) (BSSG-395)

Recombinant Anti-CEA x Anti-GD2 Bispecific Antibody (VHH-IgG) is formed by an IgG and two VHH fragments. The VHHs from an anti-GD2 antibody variable domain are respectively connected to the N terminus of the anti-CEA IgG heavy chains or light chains to form VHH-(H)IgG or VHH-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can bind two factors simultaneously. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CEA & GD2

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Targets

Target 1

CEA

Gene ID

1048

UniProt ID

A0A024R0K5

Alternative Names

CEACAM5; carcinoembryonic antigen; carcinoembryonic antigen related cell adhesion molecule 5; CEA; CD66e; meconium antigen 100

Target 2

GD2

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CEA x Anti-GD2 Bispecific Antibody (VHH-IgG) (BSSG-395). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CEA x Anti-GD2 Bispecific Antibody (VHH-IgG) (CAT#: BSSG-395)

Specifications

Targets

Customer Reviews and Q&As